tbuckley/cabot-search huggingface dataset:
AB0004 TLR10 SINGLE NUCLEOTIDE POLYMORPHISMS ARE ASSOCIATED WITH HIDRADENITIS SUPPURATIVA IN A CAUCASIAN SPANISH POPULATION (NORTHERN SPAIN)
Authors: M. Calderón-Goercke, J. G. Ocejo-Vinyals, J. Irure-Ventura, M. Gutiérrez-Larrañaga, M. A. González-Gay, I. Vilanova, J. Cantos-Mansilla, R. Blanco, M. González-López
Journal: Annals of the Rheumatic Diseases (2020)

Background: Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory cutaneous disease affecting terminal hair follicles in apocrine-gland bearing skin. The pathogenesis of HS is still unknown, although increasing evidence suggests that the immune system plays an important role. In order to study the role of innate immunity we analyzed several Toll Like Receptors (TLRs) functional single nucleotide polymorphisms (SNPs). To date, only one previous study focused about the role of TLR4 SNPs in HS showing no association with this disease. Objectives: The main goal of this study was to analyze the role of several TLRs functional SNPs in HS patients and healthy controls, in a Caucasian population from Cantabria (northern Spain). Methods: Through a case-control study, we analyzed the allele and genotype distribution of the SNPs in 106 patients with HS and 278 age and sex matched healthy control subjects for the following SNPs (TLR1 rs5743611 and rs4833095, TLR2 rs5743704 and rs5743708, TLR6 rs5743810, and TLR10 rs11096955, rs11096957 and rs4129009, by Real-Time PCR using a TaqMan assay. Results: We did not find any significant difference in the allelic distribution of the different SNPs between HS patients and controls. Regarding genotypes, only TLR10 rs11096955 (dominant, codominant and overdominant), rs11096957 (dominant, codominant and overdominant) and rs4129009 (codominant and overdominant) showed significant differences between HS patients and controls. However, no association was found when we analyzed the different TLR10 haplotypes. Conclusion: To the best of our knowledge, this is the first study showing an association of TLR10 SNPs with HS. References: [1]González-López MA. J Am Acad Dermatol. 2016; Aug;75(2):329-35. [2]González-López MA. PLoS One. 2018 Jan 4;13(1) [3]Vilanova I. J Eur Acad Dermatol Venereol. 2018 May;32(5):820-824. [4]Durán-Vian C, J Eur Acad Dermatol Venereol. 2019 Nov;33(11):2131-2136. Disclosure of Interests: Monica Calderón-Goercke: None declared, J. Gonzalo Ocejo-Vinyals: None declared, Juan Irure-Ventura: None declared, María Gutiérrez-Larrañaga: None declared, Miguel A González-Gay Grant/research support from: Pfizer, Abbvie, MSD, Speakers bureau: Pfizer, Abbvie, MSD, Iosune Vilanova: None declared, Juan Cantos-Mansilla: None declared, Ricardo Blanco Grant/research support from: AbbVie, MSD, and Roche, Speakers bureau: AbbVie, Pfizer, Roche, Bristol-Myers, Janssen, and MSD, Marcos González-López: None declared
Association Between Sex and Treatment Outcomes of Atrial Fibrillation Ablation Versus Drug Therapy
Authors: Andrea M. Russo, Emily P. Zeitler, Anna Giczewska, Adam P. Silverstein, Hussein R. Al-Khalidi, Yong-Mei Cha, Kristi H. Monahan, Tristram D. Bahnson, Daniel B. Mark, Douglas L. Packer, Jeanne E. Poole
Journal: Circulation (2021)

Among patients with atrial fibrillation (AF), women are less likely to receive catheter ablation and may have more complications and less durable results. Most information about sex-specific differences after ablation comes from observational data. We prespecified an examination of outcomes by sex in the 2204-patient CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation).
Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women
Authors: Sagar B. Dugani, M. Vinayaga Moorthy, Chunying Li, Olga V. Demler, Alawi A. Alsheikh-Ali, Paul M Ridker, Robert J. Glynn, Samia Mora
Journal: JAMA Cardiology (2021)

Risk profiles for premature coronary heart disease (CHD) are unclear.To examine baseline risk profiles for incident CHD in women by age at onset.A prospective cohort of US female health professionals participating in the Women's Health Study was conducted; median follow-up was 21.4 years. Participants included 28 024 women aged 45 years or older without known cardiovascular disease. Baseline profiles were obtained from April 30, 1993, to January 24, 1996, and analyses were conducted from October 1, 2017, to October 1, 2020.More than 50 clinical, lipid, inflammatory, and metabolic risk factors and biomarkers.Four age groups were examined (<55, 55 to <65, 65 to <75, and ≥75 years) for CHD onset, and adjusted hazard ratios (aHRs) were calculated using stratified Cox proportional hazard regression models with age as the time scale and adjusting for clinical factors. Women contributed to different age groups over time.Of the clinical factors in the women, diabetes had the highest aHR for CHD onset at any age, ranging from 10.71 (95% CI, 5.57-20.60) at CHD onset in those younger than 55 years to 3.47 (95% CI, 2.47-4.87) at CHD onset in those 75 years or older. Risks that were also noted for CHD onset in participants younger than 55 years included metabolic syndrome (aHR, 6.09; 95% CI, 3.60-10.29), hypertension (aHR, 4.58; 95% CI, 2.76-7.60), obesity (aHR, 4.33; 95% CI, 2.31-8.11), and smoking (aHR, 3.92; 95% CI, 2.32-6.63). Myocardial infarction in a parent before age 60 years was associated with 1.5- to 2-fold risk of CHD in participants up to age 75 years. From approximately 50 biomarkers, lipoprotein insulin resistance had the highest standardized aHR: 6.40 (95% CI, 3.14-13.06) for CHD onset in women younger than 55 years, attenuating with age. In comparison, weaker but significant associations with CHD in women younger than 55 years were noted (per SD increment) for low-density lipoprotein cholesterol (aHR, 1.38; 95% CI, 1.10-1.74), non-high-density lipoprotein cholesterol (aHR, 1.67; 95% CI, 1.36-2.04), apolipoprotein B (aHR, 1.89; 95% CI, 1.52-2.35), triglycerides (aHR, 2.14; 95% CI, 1.72-2.67), and inflammatory biomarkers (1.2- to 1.8-fold)-all attenuating with age. Some biomarkers had similar CHD age associations (eg, physical inactivity, lipoprotein[a], total high-density lipoprotein particles), while a few had no association with CHD onset at any age. Most risk factors and biomarkers had associations that attenuated with increasing age at onset.In this cohort study, diabetes and insulin resistance, in addition to hypertension, obesity, and smoking, appeared to be the strongest risk factors for premature onset of CHD. Most risk factors had attenuated relative rates at older ages.
Functionalized Elastomers for Intrinsically Soft and Biointegrated Electronics
Authors: Hyung Joon Shim, Sung‐Hyuk Sunwoo, Yeongjun Kim, Ja Hoon Koo, Dae‐Hyeong Kim
Journal: Advanced Healthcare Materials (2021)

Abstract Elastomers are suitable materials for constructing a conformal interface with soft and curvilinear biological tissue due to their intrinsically deformable mechanical properties. Intrinsically soft electronic devices whose mechanical properties are comparable to human tissue can be fabricated using suitably functionalized elastomers. This article reviews recent progress in functionalized elastomers and their application to intrinsically soft and biointegrated electronics. Elastomers can be functionalized by adding appropriate fillers, either nanoscale materials or polymers. Conducting or semiconducting elastomers synthesized and/or processed with these materials can be applied to the fabrication of soft biointegrated electronic devices. For facile integration of soft electronics with the human body, additional functionalization strategies can be employed to improve adhesive or autonomous healing properties. Recently, device components for intrinsically soft and biointegrated electronics, including sensors, stimulators, power supply devices, displays, and transistors, have been developed. Herein, representative examples of these fully elastomeric device components are discussed. Finally, the remaining challenges and future outlooks for the field are presented.
OP0141 Activated fibroblast-like cells in aseptic prosthesis loosening – similar or different from rheumatoid arthritis synovial fibroblasts?
Authors: T Pap, S Ohtsu, Y Shigeyama, I Sainsbury, JK Franz, JK Fernihough, M Billingham, G Pap, W Neumann, RE Gay, WK Aicher, S Gay
Journal: Annals of the Rheumatic Diseases (2001)

<h3></h3> Aseptic prosthesis loosening (APL) is an active process that is linked to the development of a synovial-like interface membrane (SLIM) at the bone-implant interface. Growing evidence suggests that the synovial membrane in rheumatoid arthritis (RA) and this SLIM share certain similarities. However, the mechanisms of SLIM formation as well as the cellular and molecular events in the activation of fibroblast-like cells remain elusive. Recently, we have established a novel animal model of SLIM formation that is based on the implantation of joint arthroplasties into intracranially self-stimulated (ICSS) Wistar rats. Data from this animal model as well as from human SLIM samples suggest that there is a subset of activated fibroblast-like cells present also in the SLIM of APL. These prosthesis-loosening fibroblasts (PLF) not only show a similar growth pattern as RA-synovial fibroblasts (RA-SF) but also exhibit features of cellular activation found in RA. Among them, the up regulation of transcription factors and the resistance against Fas-induced apoptosis are most prominent. Although PLF express a number of matrix degrading enzymes and secrete soluble factors that stimulate neighbouring cells, their role in the degradation of bone has been restricted to that of supporting bystanders. Based on most recent results, we report that PLF from the SLIM around loose joint prostheses display a highly aggressive, RA-like phenotype when implanted into SCID mice, are capable of resorbing bone <i>in vivo</i> without the help of osteoclasts and release large amounts of acidic components. As demonstrated by RT-PCR, <i>in situ</i> hybridization and immuno electron microscopy, these cells express a specific proton pump (v-ATPase) on their cell surface that may account for their ability to decalcify bone. By quantitative real time PCR, an increased expression of this v-ATPase is found in prosthesis loosening fibroblasts and rheumatoid synovial fibroblasts as compared to normal or osteoarthritic cells. Inhibition of the v-ATPase with specific inhibitors results in a decrease of pericellular acidification. Investigating the exon structure of its catalytic β1 subunit, we were able to describe a hitherto unknown v-ATPase splice variant that appears to be regulated differently in prosthesis loosening fibroblasts as compared to rheumatoid and osteoarthritic cells. The expression of specific v–ATPases on their cell membranes including novel splice variants may provide the means by which these cells are able to decalcify bone prior to its degradation. Further studies will have to clarify whether the capability of PLF to resorb bone constitutes a rather unique feature of these cells or is linked also to cellular activation in RA.
AB1015 FEATURES OF CLINICAL AND LABORATORY ACTIVITY IN IDIOPATHIC LOBULAR PANNICULITIS.
Authors: B. Belov, O. Egorova, S. Glukhova
Journal: Annals of the Rheumatic Diseases (2020)

Background: The pathological process of idiopathic lobular panniculitis (ILP) comes from disorganization of the adipose tissue which leads to its fibrosis and atrophy. It is assumed that the disease is of immunopathological nature, as evidenced by disorders of lipid peroxidation, high CIC, excess production of leptin (LEP), IL-2 and TNF. The latter is considered a key cytokine involved in the development of the disease. Objectives: to establish the relationship between the clinical picture and immuno-inflammatory parameters (CRP, LEP and TNF) in patients with ILP. Methods: We examined 67 patients (9 men, 58 women) with the ILP diagnosis verified in the Institute in 2007-2017. The age of patients ranged from 20 to 76, the average duration of the disease was 78.91[48.50] months. In addition to general clinical examination we performed immunological, histological studies, computed tomography of the chest, tuberculin samples. To determine the body mass index of patients, the values of the Quetelet index (QI) were used. Results: The disease was found in all age groups, but more than half of the patients (57%) were in the most active working age of 45-60. ILP started with painful induration of various localization, except for the face, and increased temperature reaction of the body. The mean value of QI 24.10±12.01 cm/kg corresponded to normal body weight (p=0.180). 41 patients (61.19%) demonstrated normal QI and preobesity at the age before 45 in 30.3% of cases (p=0.36). Obesity of degree II and III was recorded for 7 patients (10.44%). QI correlated with the age of patients (r=0.43, p&lt;0.05). ESR correlated with VAS pain intensity (r=0.29, p&lt;0.05), lesion area (r=0.50, p&lt;0.05), temperature increase (r=0.68, p&lt;0.05,) and CRP level (r=0.68, p&lt;0.05). The concentration of CRP correlated with VAS pain intensity (r=0.46, p&lt;0.05), lesion area (r=0.57, p&lt;0.05), stage II node (r=0.41, p&lt;0.05) and TNF–α concentration (r=0.32, p&lt;0.05). The increase of the last indicator had a direct correlation with stage II of the node (r=0.41, p&lt;0.05,) and with the level of LEP (r=0.28, p&lt;0.05), and an inverse correlation with the number of nodes (r=-0.24, p&lt;0.05). The level of LEP increased in 35 patients (52.23%), had a direct correlation with QI (r = 0.46, p&lt;0.05), the affected area (r = 0.31, p&lt;0.05), the concentration of CRP (r=0.36, p&lt;0.05) and an inverse correlation with the number of nodes (r = -0.33, p&lt;0.05). Conclusion: it is obvious that in case of ILP there is a need to increase knowledge about the markers of inflammatory activity (ESR, CRP, TNF–α and LEP) which correlated with the area of the lesion, VAS pain intensity and temperature increase. Disclosure of Interests: None declared
SARS-COV-2 infection in patients with alcohol associated hepatitis: Challenge of treatment options
Authors: M. Eisa, R. Kennedy, R. Teferra, M. Heckroth, M. Eiswerth, C. J. McClain
Journal: Hepatology (2020)

Background: Alcohol-associated hepatitis (AH) is a severe form of alcohol-associated liver disease (ALD) that is characterized by rapid onset of jaundice, anorexia, malaise;and features of the systemic inflammatory response syndrome (SIRS) SARS-CoV-2, the virus underlying the novel coronavirus infection (COVID-19), is frequently complicated by liver involvement Older patients and those with certain comorbidities including hypertension, diabetes, obesity and malignancy often have worse outcomes and increased risk of severe disease Methods: We describe two patients who had severe AH complicated by COVID-19 Results: Patient #1 was a 34-year-old male with a history of asthma, obesity and chronic alcohol abuse who presented with fatigue and dyspnea and was found to be COVID-19 positive Admission MELD was 35;WBC, 26,900 (91% neutrophils);and ferritin was 1600 ng/ml (Table 1) He was initially started on pentoxifylline and eventually received a short course of IV steroids However, ultimately he developed multiorgan failure and died of sepsis on hospital day 21 Patient #2 was a 35-year-old female with a past medical history of alcohol associated hepatitis (AH) and cirrhosis She was hospitalized for AH and then sent to a rehabilitation facility for 7 days She was then readmitted to the hospital for altered mental status Upon return to the hospital, she was noted to be afebrile, with an O2 saturation of 96% on room air, and she was hypotensive requiring IV fluids, albumin and two pressors  Admission MELD was 36;WBC, 19,400 (83% neutrophils) (Table 1) She was treated with pentoxifylline and given a short course of Neupogen;steroids were not given 'due to COVID 19 criteria' On Day 5, she died of multiorgan failure Conclusion: COVID-19 patients and AH patients have many overlapping metabolic and biochemical characteristics, including leukocytosis with marked neutrophilia, hypoalbuminemia, elevated serum ferritin levels and hypercoagulable state During the COVID pandemic there has been increased social isolation, an increase in depression, and a substantial increase in alcohol intake that will all likely lead to increased AH A major challenge is drug therapy for AH patients with COVID-19 There is uncertainty regarding the use of steroids in patients with COVID-19 Granulocyte Colony-Stimulating Factor might have adverse effects related to the cytokine storm associated with increased mortality Thus, there is a major unmet need for novel therapies for these COVID-19 patients with AH
SAT0283 SOLUBLE GUANYLATE CYCLASE REDUCED THE GASTROINTESTINAL FIBROSIS IN BLEOMYCIN-INDUCED MOUSE MODEL OF SYSTEMIC SCLEROSIS
Authors: Y. Yamamoto, T. Okano, T. Nagamoto, Y. Fujikawa, Y. Ichise, H. Yamada, I. Naka, Y. Ueda, K. Akashi, S. Sendo, A. Onishi, J. Saegusa, A. Morinobu
Journal: Annals of the Rheumatic Diseases (2020)

Background: Systemic scleroderma (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undermined, SSc is characterized by fibrosis and proliferative vascular lesions of the skin and internal organs. SSc involves the gastrointestinal tract in more than 90% of patients 1 . Soluble guanylate cyclase (sGC) is used to treat pulmonary artery hypertension (PAH), and has been shown to inhibit experimental skin fibrosis 2 . Objectives: The aim of this study is to investigate whether bleomycin (BLM)-treated mice show gastrointestinal fibrosis, and find a therapeutic strategy to the lesion. Methods: Female C57BL/6J mice were treated with BLM or normal saline by subcutaneous implantation of osmotic minipump. These mice were sacrificed on day 28 or day 42. Gastrointestinal pathologies were examined by Masson Trichrome staining. The expression of fibrosis-related genes in gastrointestinal tract were analyzed by real-time PCR, and the levels of collagen in the tissue was measured by Sircol collagen assay. To evaluate peristaltic movement, the small intestinal transport (ITR%) was calculated as [Dyeing distance×(Duodenum- Appendix)] -1 ×100 (%). We treated BLM-treated mice with soluble guanylate cyclase (sGC) or DMSO orally and analyzed them on day 42. Results: Histological examination revealed that fibrosis from lamina propria to muscularis mucosa in the esophagus was significantly increased in BLM-treated mice, suggesting that BLM induces esophageal fibrosis in C57BL/6J mice. In addition, the levels of Col3a1 and CTGF were significantly increased in BLM-treated mice. More severe fibrosis was observed in the mice sacrificed on day 42 than the mice sacrificed on day 28. The ITR% was found to be significantly lower in BLM-treated mice, suggesting that gastrointestinal peristaltic movement was reduced in BLM-treated mice. Furthermore, we demonstrated that sGC treatment significantly reduced fibrosis of esophagus and intestine in BLM-treated mice, by histological examination and Sircol collagen assay. Esophagus (Masson’s trichrome stain×100) * One way ANOVA Newman-Keuls Conclusion: These findings suggest that BLM induces gastrointestinal fibrosis in C57BL/6J mice, and treatment with sGC improves the BLM-induced gastrointestinal lesion. References: [1]Anton Emmanuel. Current management of the gastrointestinal complications of systemic sclerosis. Nat Rev Gastroenterol Hepatol. 2016; 13: 461-472. [2]Clara Dees, et al. Stimulators of Soluble Guanylate Cyclase (sGC) Inhibit experimental Skin Fibrosis of Different Aetiologies. Ann Rheum Dis. 2015;74 (8): 1621-5. Acknowledgments: : None. Disclosure of Interests: None declared
ラットメサンギウム細胞における、RARおよびRXRの異なる寄与、およびレチノイン酸誘発MKP-1発現における3つのRARサブタイプの対照的な役割
Authors: XU Qh, Konta T, Furusu A, Nakayama K, Lucio-Cazana J, Fine Lg, Kitamura M
Journal: Journal of the American Society of Nephrology (2002)
Racial and Ethnic Health Disparities Related to COVID-19
Authors: Leo Lopez, Louis H. Hart, Mitchell H. Katz
Journal: JAMA (2021)

Racial and Ethnic Health Disparities Related to COVID-19 One of the most disturbing aspects of the coronavirus disease 2019 (COVID-19) pandemic in the US is the disproportionate harm that it has caused to historically marginalized groups.Black, Hispanic, and Asian people have substantially higher rates of infection, hospitalization, and death compared with White people. 1,2According to an analysis by the Kaiser Family Foundation and the Epic Health Research Network, based on data from the Epic health record system for 7 million Black patients, 5.1 million Hispanic patients, 1.4 million Asian patients, and 34.1 million White patients, as of July 20, 2020, the hospitalization rates and death rates per 10 000, respectively, were 24.6 and 5.6 for Black patients, 30.4 and 5.6 for Hispanic patients, 15.9 and 4.3 for Asian patients, and 7.4 and 2.3 for White patients. 2American Indian persons living in the US also have been disproportionately affected by
Abstract 11588: Real World Experience With Direct Oral Anticoagulants After Watchman Implantation
Authors: Ethan Fry, Harini Bollempali, Keith Suarez, Jeffrey Michel, Javier E Banchs
Journal: Circulation (2019)

Introduction: Left atrial appendage occluders (LAAO), such as the Watchman device, have been developed as an alternative to long-term anticoagulation for stroke prevention amongst patients with atr...
SAT0175 Effects of combined treatment alendronate + alfacalcidol on bone mineral density in postmenopausal osteoporosis
Authors: K Önes, S Tetik, M Eryavuz, Ü Akarirmak, N Caglar, H Yilmaz
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> The purpose of this study was to evaluate the effect of four different treatment modalities on bone mineral density (BMD) in postmenopausal osteoporosis. <h3>Methods</h3> 170 postmenopausal women BMD (measured by dual energy X-Ray absorptiometry-DXA) T scores at least ?2,5 SD below the peak young adult mean were included in the study. The patients were randomised to four groups. 40 patients were treated with alendronate (10 mg/daily) + alfacalcidol (0,5 μg/daily) and 40 patients were treated alendronate (10 mg/daily) and 60 patients were treated alfalcidol (0,5 μg/daily) for two years. All patients received 500 mg/daily supplemental calcium to ensure adequate calcium intake. Only 500 mg of calcium were given to the control group of 30 patients. BMD was measured by total body dual-energy X-Ray absorptiometry (DPX-Lunar) in the lumbar spine and in proximal segments of the femur (neck, ward?s triangle, trochanter, inter and total hip). BMD was evalvated at baseline and after 12 and 24 months. The patients followed up for two years. <h3>Results</h3> After two years of treatment, we found significant increase of femoral neck, trochanter, ward?s triangle and lumbar spine density in alendronate + alfacalcidol group and alone alendronate group (p &lt; 0.05). Also, in the second year of treatment, the combination of alendronate + alfacalcidol showed BMD increases that were significantly higher than for alendronate (p &lt; 0.05). In the alfacalcidol group, BMD no increased significantly (p &gt; 0.05). In the placebo group (only calcium 500 mg/daily), BMD decreased significantly (p &lt; 0.05). No adverse effect were observed during the two years of the study, in particular with respect to renal function and the gastrointestinal system. <h3>Conclusion</h3> These results showed that combined treatment with alfacalcidol + alendronate was more effective than therapy with alendronate alone.